@FiercePharma: Can't stop gambling or shopping? Parkinson's meds may be to blame, JAMA study finds. Feature | Follow @FiercePharma
@EricPFierce: RT @FiercePharma: Top-read special report Monday: The top 10 most expensive drugs of 2013. Report | Follow @EricPFierce
@CarlyHFierce: Novartis recruits Nick Cannon for double-whammy flu campaign. FiercePharmaMarketing story | Follow @CarlyHFierce
> AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY) won't have to fight a whistleblower lawsuit over alleged kickbacks to a pharma benefits manager; a U.S. appeals court upheld a lower court's decision to toss the case. Report
> The U.K.'s Reckitt Benckiser saw sales growth slow in the third quarter as it prepares to spin off its pharma business by the end of this year. Report
> An epilepsy patient group is urging Congress to pass new Drug Enforcement Administration scheduling rules to speed up access to drugs for the condition. Release
> Johnson & Johnson ($JNJ) and its partner Pharmacyclics ($PCYC) asked the FDA to approve a new use for their cancer drug Imbruvica, in patients with Waldenström's macroglobulinemia. Release
> Novartis ($NVS) sued India's Dr. Reddy's Laboratories over the latter's filing for U.S. approval for a version of its blood cancer drug Gleevec. Report
> Bayer's new pulmonary arterial hypertension drug Adempas won a Prix Galien award, which recognizes achievements in pharma science. Release
Medical Device News
@FierceMedDev: 2014's most memorable medtech patent battles. Feature | Follow @FierceMedDev
@VarunSaxena2: ICYMI yesterday: Nanodevices could be unleashed by DNA-brick self-assembly. Article | Follow @VarunSaxena2
@EmilyWFierce: RIP Shabbvie. Bloomberg piece | Follow @EmilyWFierce
> Illumina up 10% on strongest growth since 2011, raises 2014 guidance. Story
> Google, KKR, Kleiner Perkins invest $542M in virtual reality eyeglass startup. Article
> FDA clears app to monitor brain health on the battlefield. More
> Q&A: CMO says Covidien wants to engage parallel review process. Editor's Corner
Biotech News
@FierceBiotech: Great panel with $BLUE, $PFE, $AGIO, $GSK and $SNY on the revolution in drug R&D. Video will be up on site tomorrow. | Follow @FierceBiotech
@JohnCFierce: Top 10 Phase III disasters of 2014. Feature | Follow @JohnCFierce
@DamianFierce: RT @DatamonitorMark: David Shlaes: "AZ has told its antibiotics researchers they should make efforts to find other jobs in near future." Blog post via Antibiotics - The Perfect Storm | Follow @DamianFierce
@EmilyMFierce: Human intestinal organoids grown in mice could help personalize treatments. FierceBiotech Research story | Follow @EmilyMFierce
> AbbVie's $55B deal for Shire is officially dead. Now what? More
> Omeros halts a Phase II Huntington's trial over alarming rat results. Story
> Despite a mid-stage miss, Cytokinetics is taking its ALS drug toward Phase III. Article
Biotech Research News
> GlaxoSmithKline drug flips off cancer mechanism in aggressive leukemia. Story
> Protein boost restores hearing in deaf mice. More
> Human intestinal organoids grown in mice could help personalize treatments. Story
> Researchers pinpoint potent anti-obesity compounds. More
> Protein switch could boost recovery after heart attack. Article
Pharma Manufacturing News
> Janssen recalls 13,500 bottles of Xarelto because of contamination. News
> Canada cuts Apotex a break on some banned drugs. Report
> BARDA calls on Novartis, GSK, Emergent to pitch in with Ebola drug. Article
> FDA will start the new year with its Office of Quality in place. Item
> Lilly closing a Puerto Rico plant next year but investing in another. More
And Finally... The U.K. government has backed access to unapproved meds for terminally ill patients. Report